Mapping of truncated O-glycans in cancers of epithelial and non-epithelial origin

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Mapping of truncated O-glycans in cancers of epithelial and non-epithelial origin. / Rømer, Troels Boldt; Aasted, Mikkel Koed Møller; Dabelsteen, Sally; Groen, Aaron; Schnabel, Julia; Tan, Edwin; Pedersen, Johannes Wirenfeldt; Haue, Amalie Dahl; Wandall, Hans Heugh.

In: British Journal of Cancer, Vol. 125, No. 9, 2021, p. 1239-1250.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Rømer, TB, Aasted, MKM, Dabelsteen, S, Groen, A, Schnabel, J, Tan, E, Pedersen, JW, Haue, AD & Wandall, HH 2021, 'Mapping of truncated O-glycans in cancers of epithelial and non-epithelial origin', British Journal of Cancer, vol. 125, no. 9, pp. 1239-1250. https://doi.org/10.1038/s41416-021-01530-7

APA

Rømer, T. B., Aasted, M. K. M., Dabelsteen, S., Groen, A., Schnabel, J., Tan, E., Pedersen, J. W., Haue, A. D., & Wandall, H. H. (2021). Mapping of truncated O-glycans in cancers of epithelial and non-epithelial origin. British Journal of Cancer, 125(9), 1239-1250. https://doi.org/10.1038/s41416-021-01530-7

Vancouver

Rømer TB, Aasted MKM, Dabelsteen S, Groen A, Schnabel J, Tan E et al. Mapping of truncated O-glycans in cancers of epithelial and non-epithelial origin. British Journal of Cancer. 2021;125(9):1239-1250. https://doi.org/10.1038/s41416-021-01530-7

Author

Rømer, Troels Boldt ; Aasted, Mikkel Koed Møller ; Dabelsteen, Sally ; Groen, Aaron ; Schnabel, Julia ; Tan, Edwin ; Pedersen, Johannes Wirenfeldt ; Haue, Amalie Dahl ; Wandall, Hans Heugh. / Mapping of truncated O-glycans in cancers of epithelial and non-epithelial origin. In: British Journal of Cancer. 2021 ; Vol. 125, No. 9. pp. 1239-1250.

Bibtex

@article{dfa226f65f654684bcff71e58bea148f,
title = "Mapping of truncated O-glycans in cancers of epithelial and non-epithelial origin",
abstract = "Background Novel immunotherapies targeting cancer-associated truncated O-glycans Tn (GalNAc alpha-Ser/Thr) and STn (Neu5Ac alpha 2-6GalNac alpha-Ser/Thr) are promising strategies for cancer treatment. However, no comprehensive, antibody-based mapping of truncated O-glycans in tumours exist to guide drug development. Methods We used monoclonal antibodies to map the expression of truncated O-glycans in >700 tissue cores representing healthy and tumour tissues originating from breast, colon, lung, pancreas, skin, CNS and mesenchymal tissue. Patient-derived xenografts were used to evaluate Tn expression upon tumour engraftment. Results The Tn-antigen was highly expressed in breast (57%, n = 64), colorectal (51%, n = 140) and pancreatic (53%, n = 108) tumours, while STn was mainly observed in colorectal (80%, n = 140) and pancreatic (56%, n = 108) tumours. We observed no truncated O-glycans in mesenchymal tumours (n = 32) and low expression of Tn (5%, n = 87) and STn (1%, n = 75) in CNS tumours. No Tn-antigen was found in normal tissue (n = 124) while STn was occasionally observed in healthy gastrointestinal tissue. Surface expression of Tn-antigen was identified across several cancers. Tn and STn expression decreased with tumour grade, but not with cancer stage. Numerous xenografts maintained Tn expression. Conclusions Surface expression of truncated O-glycans is limited to cancers of epithelial origin, making Tn and STn attractive immunological targets in the treatment of human carcinomas.",
keywords = "ACTIVE SPECIFIC IMMUNOTHERAPY, SIALOSYL-TN ANTIGEN, SIALYL-TN, BREAST-CANCER, CARBOHYDRATE ANTIGENS, PROTEIN GLYCOSYLATION, HUMAN-COLON, EXPRESSION, PROGNOSIS, SPECIFICITY",
author = "R{\o}mer, {Troels Boldt} and Aasted, {Mikkel Koed M{\o}ller} and Sally Dabelsteen and Aaron Groen and Julia Schnabel and Edwin Tan and Pedersen, {Johannes Wirenfeldt} and Haue, {Amalie Dahl} and Wandall, {Hans Heugh}",
year = "2021",
doi = "10.1038/s41416-021-01530-7",
language = "English",
volume = "125",
pages = "1239--1250",
journal = "The British journal of cancer. Supplement",
issn = "0007-0920",
publisher = "nature publishing group",
number = "9",

}

RIS

TY - JOUR

T1 - Mapping of truncated O-glycans in cancers of epithelial and non-epithelial origin

AU - Rømer, Troels Boldt

AU - Aasted, Mikkel Koed Møller

AU - Dabelsteen, Sally

AU - Groen, Aaron

AU - Schnabel, Julia

AU - Tan, Edwin

AU - Pedersen, Johannes Wirenfeldt

AU - Haue, Amalie Dahl

AU - Wandall, Hans Heugh

PY - 2021

Y1 - 2021

N2 - Background Novel immunotherapies targeting cancer-associated truncated O-glycans Tn (GalNAc alpha-Ser/Thr) and STn (Neu5Ac alpha 2-6GalNac alpha-Ser/Thr) are promising strategies for cancer treatment. However, no comprehensive, antibody-based mapping of truncated O-glycans in tumours exist to guide drug development. Methods We used monoclonal antibodies to map the expression of truncated O-glycans in >700 tissue cores representing healthy and tumour tissues originating from breast, colon, lung, pancreas, skin, CNS and mesenchymal tissue. Patient-derived xenografts were used to evaluate Tn expression upon tumour engraftment. Results The Tn-antigen was highly expressed in breast (57%, n = 64), colorectal (51%, n = 140) and pancreatic (53%, n = 108) tumours, while STn was mainly observed in colorectal (80%, n = 140) and pancreatic (56%, n = 108) tumours. We observed no truncated O-glycans in mesenchymal tumours (n = 32) and low expression of Tn (5%, n = 87) and STn (1%, n = 75) in CNS tumours. No Tn-antigen was found in normal tissue (n = 124) while STn was occasionally observed in healthy gastrointestinal tissue. Surface expression of Tn-antigen was identified across several cancers. Tn and STn expression decreased with tumour grade, but not with cancer stage. Numerous xenografts maintained Tn expression. Conclusions Surface expression of truncated O-glycans is limited to cancers of epithelial origin, making Tn and STn attractive immunological targets in the treatment of human carcinomas.

AB - Background Novel immunotherapies targeting cancer-associated truncated O-glycans Tn (GalNAc alpha-Ser/Thr) and STn (Neu5Ac alpha 2-6GalNac alpha-Ser/Thr) are promising strategies for cancer treatment. However, no comprehensive, antibody-based mapping of truncated O-glycans in tumours exist to guide drug development. Methods We used monoclonal antibodies to map the expression of truncated O-glycans in >700 tissue cores representing healthy and tumour tissues originating from breast, colon, lung, pancreas, skin, CNS and mesenchymal tissue. Patient-derived xenografts were used to evaluate Tn expression upon tumour engraftment. Results The Tn-antigen was highly expressed in breast (57%, n = 64), colorectal (51%, n = 140) and pancreatic (53%, n = 108) tumours, while STn was mainly observed in colorectal (80%, n = 140) and pancreatic (56%, n = 108) tumours. We observed no truncated O-glycans in mesenchymal tumours (n = 32) and low expression of Tn (5%, n = 87) and STn (1%, n = 75) in CNS tumours. No Tn-antigen was found in normal tissue (n = 124) while STn was occasionally observed in healthy gastrointestinal tissue. Surface expression of Tn-antigen was identified across several cancers. Tn and STn expression decreased with tumour grade, but not with cancer stage. Numerous xenografts maintained Tn expression. Conclusions Surface expression of truncated O-glycans is limited to cancers of epithelial origin, making Tn and STn attractive immunological targets in the treatment of human carcinomas.

KW - ACTIVE SPECIFIC IMMUNOTHERAPY

KW - SIALOSYL-TN ANTIGEN

KW - SIALYL-TN

KW - BREAST-CANCER

KW - CARBOHYDRATE ANTIGENS

KW - PROTEIN GLYCOSYLATION

KW - HUMAN-COLON

KW - EXPRESSION

KW - PROGNOSIS

KW - SPECIFICITY

U2 - 10.1038/s41416-021-01530-7

DO - 10.1038/s41416-021-01530-7

M3 - Journal article

C2 - 34526666

VL - 125

SP - 1239

EP - 1250

JO - The British journal of cancer. Supplement

JF - The British journal of cancer. Supplement

SN - 0007-0920

IS - 9

ER -

ID: 280233068